You need to create a user account to read this article.
With a subscription you unlock more content on BioStock.
One by one, the heavyweights are pulling the handbrake on the British Isles, when stingy politicians make it unworthy of investment. It's a shame for British pharmaceutical development and also sends...
Previous chronicles
The generalists about to jump on the bandwagon
Pfizer’s whining confirm it – Metsera is the perfect fit for Novo
All power to Sørensen – more turbulence ahead
Biotech shows increasing signs of life – is there more upside?
Big pharma ditches the UK – A stark warning
Is Nordic life science on sale?
Springtime for biotech – the thaw has begun
Integrum’s fiasco: a stain on a good record
Novo takes first step – now the market will pass its judgment
Founders cash in – is it time to sell BioArctic?
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account